Detalles de la búsqueda
1.
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
Proc Natl Acad Sci U S A
; 119(32): e2201073119, 2022 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35914167
2.
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Br J Cancer
; 129(6): 1022-1031, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37507543
3.
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Breast Cancer Res
; 22(1): 89, 2020 08 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32795346
4.
CDK8/19 Mediator kinases potentiate induction of transcription by NFκB.
Proc Natl Acad Sci U S A
; 114(38): 10208-10213, 2017 09 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28855340
5.
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Mol Cancer
; 22(1): 175, 2023 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37915024
6.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
BMC Cancer
; 18(1): 965, 2018 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30305055
7.
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
Clin Cancer Res
; 29(11): 2131-2143, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36884217
8.
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
Mol Cancer Ther
; 22(12): 1365-1375, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37788341
9.
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Breast Cancer Res Treat
; 136(3): 717-27, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23117852
10.
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
Mol Cancer Ther
; 21(5): 751-761, 2022 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35417017
11.
The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs.
Cells
; 10(1)2021 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33445730
12.
CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
Cells
; 9(3)2020 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32155786
13.
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
Cancers (Basel)
; 11(2)2019 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30743996
14.
Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis.
Science
; 363(6424): 270-275, 2019 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30573544
15.
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
Int J Oncol
; 50(6): 2221-2228, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28498399
16.
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.
Oncotarget
; 8(8): 12558-12575, 2017 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28147342
17.
Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer.
Curr Cancer Drug Targets
; 15(8): 739-49, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26452386
Resultados
1 -
17
de 17
1
Próxima >
>>